PIM1 and non-small cell lung carcinoma: In addition to the potential use of Gefitinib / PIM kinase inhibitor combination in the treatment of CRPC, this combination may be especially attractive in treatment of EGF driven tumours such as NSCLC in which Gefitinib as a single agent already has significant activity.